ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TTR-mediated Amyloidosis
Conditions
TTR-mediated Amyloidosis
Trial Timeline
Oct 1, 2013 → Aug 1, 2016
NCT ID
NCT01961921About ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion is a phase 2 stage product being developed by Alnylam Pharmaceuticals for TTR-mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01961921. Target conditions include TTR-mediated Amyloidosis.
What happened to similar drugs?
0 of 1 similar drugs in TTR-mediated Amyloidosis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01961921 | Phase 2 | Completed |
Competing Products
7 competing products in TTR-mediated Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ALN-TTR02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| ALN-TTRSC (revusiran) for subcutaneous administration | Alnylam Pharmaceuticals | Phase 2 | 32 |
| Patisiran | Alnylam Pharmaceuticals | Phase 2 | 32 |
| ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| Revusiran (ALN-TTRSC) | Alnylam Pharmaceuticals | Phase 2 | 32 |
| patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 3 | 37 |
| patisiran (ALN-TTR02) | Alnylam Pharmaceuticals | Pre-clinical | 23 |